Zimmer Biomet Holdings, Inc. ZBH NYSE

Zimmer Biomet Holdings, Inc. (ZBH) generated $1.7B in operating cash flow for fiscal year 2025. After capital expenditures of $224.5M, free cash flow was $1.47B.

Free cash flow margin was 17.9% of revenue. Cash conversion ratio was 2.41x, indicating earnings are backed by cash.

The company returned $190.3M in dividends and $487M in share buybacks to shareholders during the period.

Criteria supported by this page:

• HEALTH (67/100, Partial) — cash generation is adequate but may not fully cover debt in stressed conditions
• MOAT (65/100, Partial) — cash flow generation is present but not at levels indicating a wide moat
• INCOME (45/100) — Cash conversion ratio was 2.41x confirms earnings are backed by real cash flow

Overall SharesGrow Score: 63/100 with 2/7 criteria passed.